These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33210415)

  • 1. The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis.
    Namisaki T; Fujinaga Y; Moriya K; Yoshiji H
    Hepatol Res; 2021 Jan; 51(1):31-38. PubMed ID: 33210415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of ductular reaction and ductular-canalicular junctions in identifying severe primary biliary cholangitis.
    Overi D; Carpino G; Cristoferi L; Onori P; Kennedy L; Francis H; Zucchini N; Rigamonti C; Viganò M; Floreani A; D'Amato D; Gerussi A; Venere R; Alpini G; Glaser S; Alvaro D; Invernizzi P; Gaudio E; Cardinale V; Carbone M
    JHEP Rep; 2022 Nov; 4(11):100556. PubMed ID: 36267871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary biliary cholangitis: treatment.
    Cazzagon N; Floreani A
    Curr Opin Gastroenterol; 2021 Mar; 37(2):99-104. PubMed ID: 33492001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.
    Samur S; Klebanoff M; Banken R; Pratt DS; Chapman R; Ollendorf DA; Loos AM; Corey K; Hur C; Chhatwal J
    Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finding the cure for primary biliary cholangitis - Still waiting.
    Tanaka A; Gershwin ME
    Liver Int; 2017 Apr; 37(4):500-502. PubMed ID: 28371099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in the treatment of primary biliary cholangitis - role of obeticholic acid.
    Jhaveri MA; Kowdley KV
    Ther Clin Risk Manag; 2017; 13():1053-1060. PubMed ID: 28860789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
    Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
    J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.
    Bahar R; Wong KA; Liu CH; Bowlus CL
    Gastroenterol Hepatol (N Y); 2018 Mar; 14(3):154-163. PubMed ID: 29928160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Clinical Management of Patients with Primary Biliary Cholangitis-A Retrospective Multicenter Study from Germany.
    Wilde AB; Lieb C; Leicht E; Greverath LM; Steinhagen LM; Wald de Chamorro N; Petersen J; Hofmann WP; Hinrichsen H; Heyne R; Berg T; Naumann U; Schwenzer J; Vermehren J; Geier A; Tacke F; Müller T
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33806503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational drugs in phase II clinical trials for primary biliary cholangitis.
    Silveira MG; Lindor KD
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From pathogenesis to novel therapies in the treatment of primary biliary cholangitis.
    Ronca V; Carbone M; Bernuzzi F; Malinverno F; Mousa HS; Gershwin ME; Invernizzi P
    Expert Rev Clin Immunol; 2017 Dec; 13(12):1121-1131. PubMed ID: 28994348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
    Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation.
    Kim WR; Poterucha JJ; Jorgensen RA; Batts KP; Homburger HA; Dickson ER; Krom RA; Wiesner RH; Lindor KD
    Hepatology; 1997 Jul; 26(1):22-6. PubMed ID: 9214447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in the treatment of primary biliary cholangitis].
    Li YM; Wang QX; Ma X
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):805-809. PubMed ID: 29325272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.
    Honda A; Tanaka A; Kaneko T; Komori A; Abe M; Inao M; Namisaki T; Hashimoto N; Kawata K; Takahashi A; Ninomiya M; Kang JH; Arakawa M; Yamagiwa S; Joshita S; Umemura T; Sato K; Kaneko A; Kikuchi K; Itakura J; Nomura T; Kakisaka K; Fujii H; Kawada N; Takikawa Y; Masaki T; Ohira H; Mochida S; Yoshiji H; Iimuro S; Matsuzaki Y; Takikawa H;
    Hepatology; 2019 Dec; 70(6):2035-2046. PubMed ID: 30737815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
    Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
    Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis.
    Kawata K; Joshita S; Shimoda S; Yamashita Y; Yamashita M; Kitsugi K; Takatori S; Ohta K; Ito J; Shimoyama S; Noritake H; Suda T; Harada K
    Hepatol Res; 2021 Jan; 51(1):80-89. PubMed ID: 33080094
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.